Protalix Biotherapeutics Inc. buy stratec
Start price
03.02.18
/
50%
€5.13
Target price
04.11.21
€4.00
Performance (%)
-81.68%
End price
05.11.21
€0.94
Summary
This prediction ended on 05.11.21 with a price of €0.94. Massive losses of -81.68% were the result for the BUY prediction by stratec. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Protalix Biotherapeutics Inc. | 1.724% | 1.724% | -16.074% | 15.385% |
| iShares Core DAX® | -3.141% | 1.269% | 16.367% | 60.124% |
| iShares Nasdaq 100 | -3.518% | -1.355% | 2.670% | 101.416% |
| iShares Nikkei 225® | -3.396% | 3.283% | 17.041% | 47.915% |
| iShares S&P 500 | -2.943% | -0.533% | 1.373% | 64.215% |
Comments by stratec for this prediction
In the thread Protalix Biotherapeutics Inc. diskutieren
Protalix is a Buy for investors who are patient and brave...
Protalix has the first FDA-approved plant cell expressed protein, Elelyso for Gaucher disease, and has three other drug candidates in its pipeline.
Protalix recently inked a deal with Chiesi for the commercialization of PRX-102 worldwide (except in the USA). Phase 3 interim data for its Fabry disease franchise will be reported in 2018. PRX-102 has less antibody formation (and antibodies only stay in the body briefly).
The orphan disease market is lucrative with PRX-102 to potentially become the new standard of care.
stratec stimmt am 03.02.2018 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 5.22€ zu.
Kursziel geändert auf 2,2
Kursziel geändert auf 3,0
Kursziel geändert auf 4,0
In the thread Trading Protalix Biotherapeutics Inc.
Die von stratec gewählte maximale Laufzeit wurde überschritten